NKG2A参与抗肿瘤免疫的生物学机制及前景  

Biological mechanism and prospect of NKG2A in anti-tumor immunity

作　　者：袁航[1] 郭朗睿 谢芳[1] YUAN Hang;GUO Lang-rui;XIE Fang(Department of Pathology and Pathophysiology,School of Biology and Basic Medical Sciences,Soochow University,Suzhou 215123,China;Department of Archives and E-government,School of Social Science,Soochow University,Suzhou 215000,China)

机构地区：[1]苏州大学基础医学与生物科学学院病理学与病理生理学系,苏州215123 [2]苏州大学社会学院档案与电子政务系,苏州215000

出　　处：《现代免疫学》2024年第5期443-448,共6页Current Immunology

基　　金：国家自然科学基金(82073374,81772809)。

摘　　要：自然杀伤细胞受体第二组成员A(natural killer cell receptor groupⅡnumber A,NKG2A)是NKG2受体家族的抑制性受体成员,主要表达在以NK细胞为代表的多种免疫细胞上,研究发现NKG2A参与多种肿瘤的发生、发展。目前针对NKG2A的靶向药物已进入一系列上皮性肿瘤的临床期试验。该文通过阐述NKG2A的生物学特性及其在CD8^(+)T细胞、NK细胞等免疫细胞中的生物学作用,进而探讨NKG2A作为免疫检查点在抗肿瘤免疫中的作用机制,以期为临床抗肿瘤免疫治疗提供理论依据。Natural killer cell receptor groupⅡmember A(NKG2A)is an inhibitory receptor of the NKG2 receptor family,which is mainly expressed on a variety of immune cells represented by NK cells.Studies have also revealed that NKG2A is involved in the development of a variety of tumors.NKG2A targeting drugs are currently in clinical phase trials for multiple epithelial tumors.The review describes the biological properties of NKG2A and its regulatory role on CD8~+T cells,NK cells,and other immune cells.The review further explores the mechanism of NKG2A as an immune checkpoint in anti-tumor immunity,and provides a theoretical basis for clinical anti-tumor immunotherapy.

关 键 词：CD94/自然杀伤细胞受体第二组成员A 人类白细胞抗原E CD8^(+)T细胞 自然杀伤细胞 肿瘤免疫 

分 类 号：R392[医药卫生—免疫学]